Advertising Consistency in Argentina under GMC 25/21 Part IV

1. Key takeaways

Part IV of GMC 25/21 sets two red lines for promotional information on medical devices:

1. Any promotional information on a medical device released to the market or to consumers must be strictly consistent with the information submitted by the registration holder to the competent authority;
2. Information requiring prior approval must not be disclosed before publication through official channels.

A gap between the promotional line and the registered dossier is one of the most frequent compliance risk points in the Latin American market and a priority focus of ANMAT inspections. Internally, companies should establish a three-way consistency check across the registration documents, the label and IFU, and the promotional materials. The value of this check lies in its timing: it runs before publication, when discrepancies are cheap to fix, rather than after an inspector finds a claim that no dossier ever supported.

The enforcement logic behind the two red lines is an asymmetry of proof. The regulator holds the registration file and compares it against whatever is published in the market; the comparison is documentary, fast, and hard to contest. That is why the three-way consistency check matters operationally: it reproduces the regulator’s own comparison inside the company, before publication, while the cost of correcting a claim is a marketing edit rather than a finding in an inspection report. A compliance program that reviews in this order spends little and prevents much; one that reviews after release discovers problems at the moment they are most expensive.

2. Legal basis

3. Expert insights

Insight 1: Strict consistency covers far more than formal advertising. Product brochures, website product pages, exhibition materials, distributor training materials, e-commerce product listings, and copy inside apps all count as promotional information released to the market or to consumers. Companies routinely review only formal advertisements and overlook the two highest-risk zones: e-commerce listings and training materials. These channels are updated frequently, often by commercial teams without regulatory review, and they are precisely the artifacts inspectors can collect during a routine market sweep. A single overstated claim on a product page can contradict a dossier that is otherwise impeccable.

Insight 2: Consistency with the label and IFU is the other face of the same problem. Labels and IFUs must be in Spanish and carry nine required elements, and promotional information must in turn be consistent with what was submitted to ANMAT. The correct internal response is therefore a three-way consistency check across registration documents, label and IFU, and promotional materials, rather than three separate reviews that never meet. When the three streams are reviewed independently, each can pass while the set is inconsistent; when reviewed together, the contradiction surfaces immediately and can be resolved before anything is published.

Insight 3: Information requiring prior approval must not be disclosed early, and this rule targets changes and new products. If an indication expansion or a performance claim is still under approval, it cannot be used in promotion ahead of time. Under commercial pressure, companies are tempted to build momentum early, and this is exactly the violation that is easiest to verify: the regulator holds the dossier, the claim is public, and the timeline speaks for itself. Early promotion of unapproved claims converts a routine approval process into an enforcement case, and it can also complicate the approval of the very change being promoted.

Insight 4: Consistency obligations scale with the number of languages and channels a company uses. A claim translated loosely into Spanish can be perfectly consistent in the English master and materially overstated in the Argentine market, and the regulator assesses only what is published locally. For this reason, the consistency check should operate on the published artifact, in the published language, rather than on the upstream source material. Distributor-created content deserves particular attention, since it is produced outside the manufacturer’s document control yet remains promotional information released to the market. A practical pattern is a pre-approved claims list: the registration holder maintains the definitive wording of intended purpose, indications, performance parameters, and warnings, and any material, internal or distributor-generated, is cleared by matching its claims against that list rather than by free-text review.

4. Practical recommendations

1. Build a three-way consistency checklist. Compare registration documents, label and IFU, and promotional materials item by item across four elements: intended purpose, indications, performance parameters, and warnings.
2. Bring e-commerce listings and training materials into the review scope. Do not review only formal advertisements; these two categories typically show the higher violation rate.
3. Tag pending-approval information as not approved. In the internal asset library, flag statements that have not yet been approved separately, and prohibit their external use until the flag is cleared.
4. Name a final reviewer for promotional compliance. All external materials are signed off for consistency by the registration holder or by the manufacturer’s regulatory function before release, with review records retained.

5. Verification checklist

• □ A three-way consistency checklist across registration documents, label and IFU, and promotional materials has been established
• □ The four elements of intended purpose, indications, performance parameters, and warnings have been compared item by item
• □ E-commerce listings and distributor training materials have been brought into the review scope
• □ Statements under approval have been tagged as not approved in the asset library
• □ A final reviewer for promotional compliance has been designated
• □ Review records for promotional materials have been retained

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly handling classification assessment, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and label localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance, and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience, tracking the developments of regulators worldwide. All external content follows the drafting standard of conclusions first, traceable basis, and verifiable numbers. For a market access plan tailored to your specific product for Argentina or the MERCOSUR region, contact the GRZAN regulatory team at info@grzanglobal.com.